Brian van Tine, MD
Medical Oncology · Saint Peters, MONPI 1235227794
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $36,174 of the $52,249 with a category attached, or 69.2%. 17 manufacturers reported payments, led by Daiichi Sankyo Inc. at 44.8% of the total.
Across 83 payments — averaging $629.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$23K
- Regeneron$5K
- Ipsen Biopharmaceuticals, Inc$5K
- Deciphera Pharmaceuticals Inc.$4K
- Boehringer Ingelheim$3K
- Aadi Bioscience, Inc.$3K
- plus $9K from 11 others
Across 1,142 payments — averaging $8088.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$1.3M
- PTC Therapeutics, Inc.$1.1M
- Deciphera Pharmaceuticals Inc.$1.1M
- Exelixis Inc.$1.1M
- GSK$848K
- Aadi Bioscience, Inc.$696K
- plus $3.1M from 28 others
What the payments were for
- Consulting fees$36,17469%
- Speaking & faculty fees$7,25214%
- Travel & lodging$5,13210%
- Food & beverage$3,6917%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 37 | $23,396 |
| Regeneron | 2 | $4,974 |
| Ipsen Biopharmaceuticals, Inc | 5 | $4,781 |
| Deciphera Pharmaceuticals Inc. | 5 | $4,481 |
| Boehringer Ingelheim | 1 | $2,960 |
| Aadi Bioscience, Inc. | 10 | $2,733 |
| GSK | 4 | $2,490 |
| PTC Therapeutics, Inc. | 5 | $2,073 |
| Boehringer Ingelheim International GmbH | 1 | $1,950 |
| Bayer | 1 | $1,250 |
| Exelixis Inc. | 3 | $358 |
| Eli Lilly | 2 | $238 |
| Rigel Pharmaceuticals, Inc. | 2 | $208 |
| Beone Medicines USA, Inc. | 1 | $157 |
| Gilead | 1 | $124 |
| Array Biopharma Inc | 2 | $45 |
| Blueprint Medicines Corporation | 1 | $31 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$52,249 in reported general payments places this provider in the 85th percentile of 144 medical oncology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 11 | $159,686 |
| XareltoRivaroxaban | 15 | $9,994 |
| Oxycodone Hcl | 124 | $2,830 |
| Prochlorperazine Maleate | 57 | $1,138 |
| Morphine Sulfate ErMorphine Sulfate | 50 | $1,092 |
| Gabapentin | 86 | $877 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 16 | $708 |
| Dexamethasone | 40 | $470 |
| Methadone Hcl | 15 | $420 |
| Duloxetine Hcl | 16 | $343 |
| Pregabalin | 19 | $277 |
| Ondansetron Hcl | 31 | $200 |
| Levothyroxine Sodium | 15 | $155 |
| Methylphenidate Hcl | 15 | $154 |
| Zolpidem Tartrate | 30 | $121 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Saint Peters
- Tanya WildesSaint Peters$21K
- Ashley FrithSaint Peters$14K
- Leonid ShunyakovBolivar$2.1M
- Timothy PluardKansas City$664K
- Brad KahlSaint Louis$336K
- Michael NaughtonCape Girardeau$249K
- Russell PachynskiSaint Louis$226K
- Mark SchroederSaint Louis$198K
- George AnsstasSaint Louis$189K
- Ravi VijSaint Louis$153K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.